Actuate Therapeutics, Inc. Common stock (ACTU)vsInsmed Inc (INSM)
ACTU
Actuate Therapeutics, Inc. Common stock
$2.32
+4.98%
HEALTHCARE · Cap: $136.67M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
ACTU leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ACTU
Avoid22
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ACTU
ACTU has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ACTU
The primary concerns for ACTU are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ACTU profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ACTU generates stronger free cash flow (-7M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Actuate Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients facing serious diseases, with a particular focus on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials aimed at addressing significant unmet medical needs and enhancing patient outcomes. By concentrating on novel therapeutic mechanisms, Actuate is building a robust pipeline with the potential for strategic growth and investor value creation, positioning itself as a key player in the biotechnology landscape as it strives to make a meaningful impact.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?